Bispebjerg Hospital
Copenhagen, Copenhagen NV, 2400, Denmark
NCT Number: NCT02764021
Scientific evidence for the dietary treatment of type 2 diabetes (T2D) is insufficient. The study group hypothesizes that a lower carbohydrate content in the diabetic diet than the recommended 55 energy percentage (E%) will decrease the postprandial glucose excursion. This will reduce postprandial insulin concentration, which together with lower glucose concentration leads to less fat accumulation in the liver and muscle tissue, resulting in an improved insulin sensitivity which together with a reduced glucose load improves the glucose metabolism. This clinical study will examine in subjects with type 2 diabetes the effect of highly controlled dietary low carbohydrate intervention on metabolic pathways with respect to insulin action, pancreatic islet function, lipid metabolism, ectopic fat accumulation, incretin hormones, low grade inflammation in plasma and adipose tissue, novel measures of fatty acid metabolism, and heart rate variability, respectively. The studies exhibit the potential to reform dietary recommendation aiming to prevent and ameliorate type 2 diabetes.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Copenhagen, Copenhagen NV, 2400, Denmark
The study will be performed as a randomized 12 weeks controlled, cross-over trial, which will address the effects on T2D of an isoenergetic low carbohydrate diet (carbohydrate 30 E%, protein 30 E%, fat 40 E%) compared to an isoenergetic control diet (carbohydrate 50 E%, protein 17 E%, fat 33 E%) currently recommended to individuals with T2D. The study is extended with 24 weeks on an isoenergetic low carbohydrate diet to examine the prolonged effect of the experimental diet on T2D and its pathophysiology. To test the hypothesis that the isoenergetic control diet is detrimental to glucose metabolism after only a short transition to this diet, the participants are reinforced to eat that diet during 6 weeks after the 24 weeks on low carbohydrate/high protein diet.
The study includes n=30 subjects with T2D. All study participants will be provided all meals for both the low carbohydrate diet and the control diet for free in the first part of the study, i.e. week 0 to 12, and these food items will be prepared and distributed from the research kitchen of the Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Denmark to optimize compliance and adherence to the prescriped diet. During the isoenergetic diet study weight stability is reinforced to facilitate interpretation of the diet effect. All diets will be isoenergetic in accordance with the participant's estimated daily total energy expenditure (TEE). A dual energy X-ray absorptiometry (DXA) scan will be undertaken to determine body composition for each participant in order to estimate daily resting energy expenditure (REE). To estimate TEE, physical activity level expressed as PAL = TEE / REE, will be estimated. If a participant develops weight loss or weight gain at three consecutive measurements and/or lose or gain > 1kg of weight compared to baseline, the amount of energy in the diet wil be adjusted accordingly to enforce weight stability throughout the full duration of the study.
Measurements includes glycated hemoglobin (HbA1c) and fasting glucose, insulin, C-peptide and non-esterified fatty acids (NEFA) every 2 weeks during the first 12 weeks of the study and every 4 weeks from week 12.
At baseline, week 6, 12, 36 and 42, respectively larger measurement programs will be undertaken including insulin modified frequently sampled intravenous glucose tests (IM-FSIGT) and meal tests by use of Minimal Modelling, magnetic resonance imaging (MRi) for fat content in liver, abdomen and muscle, adipose tissue biopsies, continous glucose monitoring for 48-hours including diurnal blood pressure and Holter recording.
A standard meal will be provided for dinner a day prior to the measurement programs at week 0, 36 and 42. At weeks 6 and 12 the participants will intake their assigned meals. Participants will be informed to refrain from any strenuous physical activity and alcohol intake two days prior to and during the measurement program days.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Macronutritional composition: Carbohydrate 30 E%, Protein 30 E%, Fat 40 E%
Macronutritional composition: Carbohydrate 50 E%, Protein 13 E%, Fat 17 E%
Time frame: 42 weeks
Changes in HbA1c during a fully controlled dietary cross-over intervention from baseline to week 6 will be compared to changes in HbA1c from week 6 to week 12. Changes in HbA1c will be assessed from week 12 to week 36 during a prolonged period where the participants receive dietician guidance to reinforce coherence to the low carbohydrate diet. HbA1c will be assessed at a follow-up visit at week 42. In addition HbA1c will be meassured every 14 days during the first 12 weeks, and every 4 weeks during the 24 weeks prolonged period. HbA1c will be expressed in mmol/mol.
Time frame: 36 weeks
HRV will be assessed by a Holter monitor (model RZ 153+12 from Rozinn) at baseline, week 6, 12 and 36.
Time frame: 36 weeks
DBP will be assessed by a blood pressure monitor (model 90217 from Spacelabs Healthcare) at baseline, week 6, 12 and 36.
Time frame: 36 weeks
Changes in insulin sensitivity will be measured using the minimal model technique based on a insulin modified frequently sample intravenous glucose test (IM-FSIGT) at baseline, week 6, 12 and 36.
Time frame: 36 weeks
Changes in beta-cell function will be measured using the minimal model technique based on a insulin modified frequently sample intravenous glucose test (IM-FSIGT) at baseline, week 6, 12 and 36.
Time frame: 36 weeks
Changes in GLP-1 will be measured during a 4-hour (4-h) mixed meal test (MMT) at baseline, week 6, 12 and 36. GLP-1 will be expressed in pmol/L.
Time frame: 36 weeks
Changes in GIP will be measured during a 4-h MMT at baseline, week 6, 12 and 36. GIP will be expressed in pmol/L.
Time frame: 36 weeks
Changes in IGF-1 will be measured during a 4-h MMT at baseline, week 6, 12 and 36. IGF-1 will be expressed in ng/mL.
Time frame: 36 weeks.
Changes in IGFBP-1 will be measured during a 4-h MMT at baseline, week 6, 12 and 36. IGFBP-1 will be expressed in ng/mL.
Time frame: 36 weeks.
Changes in GH will be measured during a 4-h MMT at baseline, week 6, 12 and 36. GH will be expressed in ng/mL.
Time frame: 36 weeks
Changes in CCK will be measured during a 4-h MMT at baseline, week 6, 12 and 36. CCK will be expressed as pmol/L.
Time frame: 36 weeks
Changes in PYY will be measured during a 4-h MMT at baseline, week 6, 12 and 36. PYY will be expressed as pmol/L.
Time frame: 36 weeks
Changes in ghrelin will be measured during a 4-h MMT at baseline, week 6, 12 and 36. Ghrelin will be expressed as pmol/L.
Time frame: 36 weeks
Changes in liver, skeletal muscle and visceral adipose tissue will be assessed by magnetic resonance imaging (MRi) at baseline, week 6, 12 and 36.
Time frame: 36 weeks.
Changes in subjective satiety will be assessed by a self-reported visual analog scale (VAS) questionnaire in relation to a 4-h MMT at baseline, week 6, 12 and 36.
Time frame: 36 weeks.
Changes will be assessed by a self-reported hospital anxiety and depression scale (HADS) questionnaire at baseline, week 6, 12 and 36.
Time frame: 36 weeks.
Changes in insulin will be assessed during a 4-h MMT and during a IM-FSIGT-test at baseline, week 6, 12 and 36. In addition insulin will be meassured every 14 days during the first 12 weeks, and every 4 weeks during the last 24 weeks. Insulin will be expressed in pmol/L.
Time frame: 36 weeks.
Changes in C-peptide will be assessed during a 4-h MMT and during a IM-FSIGT-test at baseline, week 6, 12 and 36. In addition C-peptide will be measured every 14 days during the first 12 weeks, and every 4 weeks during the last 24 weeks. C-peptide will be expressed in pmol/L.
Time frame: 36 weeks.
Changes in NEFA will be assessed during a 4-h MMT and during a IM-FSIGT-test at baseline, week 6, 12 and 36. In addition NEFA will be meassured every 14 days during the first 12 weeks, and every 4 weeks during the last 24 weeks. NEFA will be expressed in micromol/L.
Time frame: 36 weeks
Changes in blood glucose will be assessed during a 4-h MMT and during a IM-FSIGT-test at baseline, week 6, 12 and 36. Blood glucose will be expressed as mmol/L.
Time frame: 36 weeks.
Changes in IGFBP-1 will be measured during a 4-h MMT at baseline, week 6, 12 and 36. IGFBP-1 will be expressed in ng/mL.
Bispebjerg Hospital
Other
Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes; Mechanisms of Effective Therapy of Diabetes by Selective Choice of Macronutrients. The Isoenergetic Study.
Acronym: CutDM-iso
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04255433
Diabetes Mellitus, Diabetes Mellitus, Type 2
Birmingham, Alabama, United States
View Trial DetailsNCT01354977
Diabetes Mellitus, Diabetes Mellitus, Type 2
The Bronx, New York, United States
View Trial DetailsNCT02004886
Diabetes Mellitus, Diabetes Mellitus, Type 2
View Trial DetailsNCT00736879
Diabetes Mellitus, Diabetes Mellitus, Type 2
Litchfield Park, Arizona, United States
View Trial Details